Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Biogen Idec Inc (BIIB)  
$230.57 0.53 (0.23%) as of 4:30 Fri 5/17


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 153,880,000
Market Cap: 35.48(B)
Last Volume: 985,059 Avg Vol: 1,343,380
52 Week Range: $190.52 - $313.41
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    S&P COMPOSITE 1500     NASDAQ BIOTECHNOLOGY
    NASDAQ COMPOSITE     NASDAQ-100
    S&P 500     NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    : 6.9
Insider 3/6 Months : 7.5
Guru Rank Number :  1040
Guru Rank Value     : -1
Guru Occurances    : 2

 

            6 Months   1 Year   2 Year  
 
Company Profile   Biogen is a biopharmaceutical company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Co. has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA) and Alzheimer's disease. Co. also commercialize biosimilars of biologics and focuses on improving its pipeline in neuroscience and immunology. Co.'s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 455 455 455
Total Buy Value $0 $101,256 $101,256 $101,256
Total People Bought 0 1 1 1
Total Buy Transactions 0 1 1 1
Total Shares Sold 355 1,626 2,138 11,088
Total Sell Value $77,779 $385,230 $524,266 $3,190,794
Total People Sold 1 1 1 2
Total Sell Transactions 2 6 8 12
End Date 2024-02-18 2023-11-17 2023-05-19 2022-05-19

   
Records found: 2109
  Page 20 of 85  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Karaboutis Adriana EVP, Tech, Bus. Sol & Corp Aff   •       •      –    2016-02-25 4 AS $261.90 $22,000 D/D (84) 8,127     -
   Sandrock Alfred EVP CMO Neuro & Neurodegenerat   •       •      –    2016-02-25 4 AS $261.90 $47,928 D/D (183) 7,990     -
   Scangos George A Chief Executive Officer   •       •      –    2016-02-23 4 D $258.99 $361,291 D/D (1,395) 61,417     -
   Scangos George A Chief Executive Officer   •       •      –    2016-02-23 4 OE $0.00 $0 D/D 2,964 62,812     -
   Holtzman Steven H EVP Corporate Development   •       •      –    2016-02-23 4 D $258.99 $70,704 D/D (273) 8,326     -
   Holtzman Steven H EVP Corporate Development   •       •      –    2016-02-23 4 OE $0.00 $0 D/D 579 8,599     -
   Karaboutis Adriana EVP, Tech, Bus. Sol & Corp Aff   •       •      –    2016-02-23 4 D $258.99 $41,956 D/D (162) 8,211     -
   Karaboutis Adriana EVP, Tech, Bus. Sol & Corp Aff   •       •      –    2016-02-23 4 OE $0.00 $0 D/D 498 8,373     -
   Artavanis-Tsakonas Spyridon SVP, Chief Scientific Officer   •       •      –    2016-02-23 4 D $258.99 $12,432 D/D (48) 2,549     -
   Artavanis-Tsakonas Spyridon SVP, Chief Scientific Officer   •       •      –    2016-02-23 4 OE $0.00 $0 D/D 145 2,597     -
   Sandrock Alfred EVP CMO Neuro & Neurodegenerat   •       •      –    2016-02-23 4 D $258.99 $42,474 D/D (164) 8,173     -
   Sandrock Alfred EVP CMO Neuro & Neurodegenerat   •       •      –    2016-02-23 4 OE $0.00 $0 D/D 347 8,337     -
   Covino Gregory F VP, Chief Accounting Officer   •       •      –    2016-02-23 4 D $258.99 $5,698 D/D (22) 2,687     -
   Covino Gregory F VP, Chief Accounting Officer   •       •      –    2016-02-23 4 OE $0.00 $0 D/D 66 2,709     -
   Koppel Adam EVP, Strategy and Bus. Dev.   •       •      –    2016-02-23 4 D $258.99 $25,381 D/D (98) 1,865     -
   Koppel Adam EVP, Strategy and Bus. Dev.   •       •      –    2016-02-23 4 OE $0.00 $0 D/D 301 1,963     -
   Cox John EVP Pharmaceutical Oper & Tech   •       •      –    2016-02-23 4 D $258.99 $98,934 D/D (382) 30,516     -
   Cox John EVP Pharmaceutical Oper & Tech   •       •      –    2016-02-23 4 OE $0.00 $0 D/D 810 30,898     -
   Dipietro Kenneth EVP Human Resources   •       •      –    2016-02-23 4 D $258.99 $77,697 D/D (300) 3,937     -
   Dipietro Kenneth EVP Human Resources   •       •      –    2016-02-23 4 OE $0.00 $0 D/D 636 4,237     -
   Alexander Susan H EVP, Chief Legal Officer   •       •      –    2016-02-23 4 D $258.99 $77,697 D/D (300) 31,840     -
   Alexander Susan H EVP, Chief Legal Officer   •       •      –    2016-02-23 4 OE $0.00 $0 D/D 636 32,140     -
   Clancy Paul J Executive VP and CFO   •       •      –    2016-02-23 4 D $258.99 $70,704 D/D (273) 26,870     -
   Clancy Paul J Executive VP and CFO   •       •      –    2016-02-23 4 OE $0.00 $0 D/D 579 27,143     -
   Sandrock Alfred EVP CMO Neuro & Neurodegenerat   •       •      –    2016-02-17 4 AS $256.16 $184,948 D/D (722) 7,990     -
  2109 Records found
  Previous  20  21  22  23  24  25  26  27  28  29  Next   
  Page 20 of 85
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us